Dr. Michael J. Glantz, MD

Dr. Glantz practices at Berkshire Medical Center in Pittsfield, Massachusetts, part of Berkshire Health Systems.

Dr. Glantz's NPI, 1568457695, was assigned on September 14, 2005. Dr. Glantz graduated from Warren Alpert Medical School of Brown University in 1984. Dr. Glantz holds Pennsylvania license MD439695.

Dr. Glantz's primary practice is Berkshire Medical Center, at 725 North Street, Pittsfield, MA 01201 in Berkshire County. The practice phone is (413) 447-2000.

Dr. Glantz's primary practice is Berkshire Medical Center in Pittsfield, Massachusetts, part of Berkshire Health Systems. Dr. Glantz is also affiliated with North Adams Regional Hospital. The medical group on file is Berkshire Faculty Services. Dmand AI also links Dr. Glantz to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Glantz practices, 3 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Glantz's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Glantz is licensed in Pennsylvania.

CMS data shows 44 Medicare services from Dr. Glantz across 2 procedure codes in 2023, for 17 Medicare patients. Medicare paid $2,552 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 17 Medicare patients who saw Dr. Glantz in 2024. The largest group is 85 and over, with 0 patients. 75% of them have high blood pressure, and 71% have high cholesterol. Their average risk score is 2.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Glantz's median patient age at 74, with 52% women.

In 2024, Dr. Glantz wrote 112 Medicare Part D claims for 20 patients. 95% of them were for generic drugs. CMS names the drug for 34 of them, across 1 drug with 11 or more claims each, at $1,208 in total drug cost. In 2023, CMS named 86 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Glantz for performance year 2024, reported as part of a group. Dr. Glantz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 60 papers to Dr. Glantz, published from 2010 to 2025. 2016 was the busiest year, with 6. The most frequent topics are Brain Neoplasms, Central Nervous System Neoplasms and Glioblastoma. Dr. Glantz has published most often in J Neurosurg. Dr. Glantz's most frequent co-authors are Brad E. Zacharia, Dawit Gebremichael Aregawi, MD and Jonas M. Sheehan, MD.

Dmand AI links Dr. Glantz to 5 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Glioblastoma, Astrocytoma and Gliosarcoma.

CMS Open Payments shows 15 general payments to Dr. Glantz from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Novocure Inc. paid the most, $718. It also lists 6 research payments totaling $866 in 2016.

Dr. Glantz graduated from Warren Alpert Medical School of Brown University in 1984.